Haupt Pharma has successfully passed an inspection by the FDA at its Amareg site in Regensburg, Germany without any FDA-483 observation issued. Haupt Pharma Amareg provides contract manufacturing, packaging and quality control in many dosage forms. The company specializes in solid dosage forms with highly active substances.

“The management board congratulates Haupt Pharma Amareg on its successful completion of the FDA inspection. This is a fundamental element in the continuing efforts to further increase the value and appeal of this site,” said Dr Karl Heinz Brücher, chief operating officer of Haupt Pharma.